IP Library Granted Patent US 7,932,252
Granted Patent B2
US 7,932,252 · App. 11/596,147 · Granted Apr 26, 2011

Aryl sulfonamides

Assignee: ChemoCentryx, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,932,252
App. No.
11/596,147
Granted
Apr 26, 2011
Kind
B2
Abstract

The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.

Claims (20)

1. A compound of the formula (III), or a salt thereof:

where

Ar 1 is a substituted or unsubstituted C 6-10 aryl or substituted or unsubstituted 5- to 10-membered heteroaryl; each having 0 to 5 substituents selected from the group consisting of halogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, —CN, —C(O)R 3 , —CO 2 R 3 , —C(O)NR 3 R 4 , —OR 3 , —OC(O)R 3 , —OC(O)NR 3 R 4 , —NO 2 , —NR 5 C(O)R 3 , —NR 5 C(O)NR 3 R 4 , —NR 3 R 4 , —NR 5 CO 2 R 3 , —NR 5 S(O) 2 R 3 , —SR 3 , —S(O)R 3 , —S(O) 2 R 3 , —S(O) 2 NR 3 R 4 , substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocyclyl;

suitable substituted C 1-8 alkyl, substituted C 2-8 alkenyl, or substituted C 2-8 alkynyl may have from 1-5 substituents independently selected from the group consisting of halogen, —OH, —CN, —NO 2 , ═O, —OC(O)R 3 , —OR 3 , —C(O)R 3 , —C(O)NR 3 R 4 , —OC(O)NR 3 R 4 , —NR 4 C(O)R 3 , —NR 3 C(O)NR 4 R 5 , —CO 2 R 3 , —NR 3 R 4 , —NR 4 CO 2 R 3 , —SR 3 , —S(O)R 3 , —S(O) 2 R 3 , —S(O) 2 NR 3 R 4 , —NR 3 S(O) 2 R 4 , unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heterocyclyl;

suitable substituted C 6-10 aryl, substituted 5- to 10-membered heteroaryl, or substituted 3- to 10-membered heterocyclyl, may have from 1-4 substituents independently selected from the group consisting of halogen, unsubstituted C 1-8 alkyl, unsubstituted C 1-8 haloalkyl, —CN, —NO 2 ,

—OR 3 , ═O, —OC(O)R 3 , —CO 2 R 3 , —C(O)R 3 , —C(O)NR 3 R 4 , —OC(O)NR 3 R 4 , —NR 4 C(O)R 3 , —NR 3 C(O)NR 4 R 5 , —NR 3 R 4 , —NR 4 CO 2 R 3 , —SR 3 , —S(O)R 3 ,

—S(O) 2 R 3 , —S(O) 2 NR 3 R 4 , and —NR 3 S(O) 2 R 4 ;

where R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 6-10 aryl, 5- to 10-membered heteroaryl, and 3- to 10-membered heterocycle, or where R 3 and R 4 , together with the atom(s) to which they are attached, form an substituted or unsubstituted 5-, 6-, or 7-membered ring;

where the aliphatic and aromatic portions of R 3 , R 4 and R 5 can be substituted with from 1 to 3 substituents selected from the group consisting of halogen, —OH, —OR m , —OC(O)NHR m , —OC(O)NR m R n , —SH, —SR m , —S(O)R m , —S(O) 2 R m , —S(O) 2 NH 2 , —S(O) 2 NHR m , —S(O) 2 NR m R m , —NHS(O) 2 R m , —NR m S(O) 2 R n , —C(O)NH 2 , —C(O)NHR m , —C(O)N(R m ) 2 , —C(O)R m , —NHC(O)R m , —NR m C(O)R n , —NHC(O)NH 2 , —NR m C(O)NH 2 , —NR m C(O)NHR n , —NHC(O)NHR m , —NR o C(O)NR m R n , —NHC(O)N(R m ) 2 , —CO 2 H, —CO 2 R m , —NHCO 2 R m , —NR m CO 2 R n , —CN, —NO 2 , —NH 2 , —NHR n , —NR m R n , —NR m S(O)NH 2 and —NR m S(O) 2 NHR n , where R m ,R n , and R o are each independently unsubstituted C 1-6 alkyl;

Y 1 , Y 2 , Y 3 , and Y 4 are each independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 1-4 alkyl, —CN, —C(O)R 6 , —CO 2 R 6 , —OR 6 , —NO 2 , —SR 6 , —S(O)R 6 , and —S(O) 2 R 6 ;

where substituted C 1-4 alkyl can have from 1 to 3 substituents independently selected from the group consisting of halogen, —OH, —OR 6 , —CN, —NO 2 , ═O, —OC(O)R 6 , —CO 2 R 6 , —C(O)R 6 , —C(O)NR 6 R 13 , —OC(O)NR 6 R 13 , —NR 13 C(O)R 6 , —NR 6 C(O)NR 13 R 14 , —NR 6 R 13 , —NR 13 CO 2 R 6 , —SR 6 , —S(O)R 6 , —S(O) 2 R 6 , —S(O) 2 NR 6 R 13 , and —NR 13 S(O) 2 R 6 ; where R 6 , R 13 , and R 14 are independently selected from the group consisting of hydrogen, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 6-10 aryl, and 5- to 10-membered heteroaryl; and

where the aliphatic and aromatic portions of R 6 , R 13 , and R 14 can be substituted with from 1 to 3 substituents selected from the group consisting of halogen, —OH, —OR m , —OC(O)NHR m , —OC(O)NR m R n , —SH, —SR m , —S(O)R m , —S(O) 2 R m , —S(O) 2 NH 2 , —S(O) 2 NHR m , —S(O) 2 NR m R n , —NHS(O) 2 R m , —NR m S(O) 2 R n , —C(O)NH 2 , —C(O)NHR m , —C(O)N(R m ) 2 , —C(O)R m , —NHC(O)R m , —NR m C(O)R n , —NHC(O)NH 2 , —NR m C(O)NH 2 , —NR m C(O)NHR n , —NHC(O)NHR m , —NR o C(O)NR m R n , —NHC(O)N(R m ) 2 , —CO 2 H, —CO 2 R m , —NHCO 2 R m , —NR m CO 2 R n , —CN, —NO 2 , —NH 2 , —NHR n , —NR m R n , —NR m S(O)NH 2 and —NR m S(O) 2 NHR n , where R m , R n , and R o are each independently unsubstituted C 1-6 alkyl;

Ar 2 is a substituted or unsubstituted isoquinolinyl, quinolizinyl, pyrrolizinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, benzotriazinyl, purinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indolizinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, pyrazolopyridinyl, imidazopyridinyl, pyridinopyridinyl, pyridinopyrimidinyl, pyridinopyridizinyl, pyridinopyrazinyl, triazolopyridinyl, pyrrolopyrazinyl, imidazotriazinyl, imidazopyrimidinyl, naphthyridinyl, benzothiazolyl, benzofuranyl, benzothienyl, indolyl, azaindolyl, benzopyrrolyl, quinolyl, isoquinolyl, indazolyl, pteridinyl, or benzisothiazolyl having 0 to 4 substituents selected from the group consisting of halogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, —CN, ═O, —NO 2 , —OR 7 , —OC(O)R 7 , —CO 2 R 7 , —C(O)R 7 , —C(O)NR 8 R 9 , —OC(O)NR 8 R 9 , —NR 7 C(O)R 8 , —NR 7 C(O)NR 8 R 9 , —NR 8 R 9 , —NR 7 CO 2 R 8 , —SR 7 , —S(O)R 7 , —S(O) 2 R 7 , —S(O) 2 NR 8 R 9 , —NR 7 S(O) 2 R 8 , substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocyclyl;

suitable substituted C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl may have from 1 to 5 substituents independently selected from the group consisting of halogen, —OH, —OR 7 , —CN, —NO 2 , ═O, —OC(O)R 7 , —CO 2 R 7 , —C(O)R 7 , —C(O)NR 7 R 8 , —OC(O)NR 7 R 8 , —NR 7 C(O)R 8 , —NR 7 C(O)NR 8 R 9 , —NR 7 R 8 , —NR 7 CO 2 R 8 , —SR 7 , —S(O)R 7 , —S(O) 2 R 7 , —S(O) 2 NR 7 R 8 , —NR 7 S(O) 2 R 8 , unsubstituted or substituted phenyl, unsubstituted or substituted C 5-6 heteroaryl, or unsubstituted or substituted C 3-6 heterocyclyl;

suitable substituted aryl, heteroaryl and heterocyclyl substituents may have from 1 to 5 substituents independently selected from the group consisting of halogen, —OR 7 , —CN, —NO 2 , ═O, —OC(O)R 7 , —CO 2 R 7 , —C(O)R 7 , —C(O)NR 7 R 8 , —OC(O)NR 7 R 8 , —NR 7 C(O)R 8 , —NR 7 C(O)NR 8 R 9 , —NR 7 R 8 , —NR 7 CO 2 R 8 , —SR 7 , —S(O)R 7 , —S(O) 2 R 7 , —S(O) 2 NR 7 R 8 , —NR 7 S(O) 2 R 8 , unsubstituted C 3-6 heterocyclyl, unsubstituted C 1-8 alkyl, and unsubstituted C 1-8 haloalkyl;

where R 7 , R 8 and R 9 are each independently selected from the group consisting of hydrogen, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 6-10 aryl, 5 to 10 membered heteroaryl and 3- to 10-membered heterocycle, or R 7 , R 8 and R 9 , may together with the atom(s) to which they are attached, form a substituted or unsubstituted 5-, 6-, or 7-membered ring, and

where the aliphatic and aromatic portions of R 7 , R 8 and R 9 can be substituted with 1 to 3 substituents selected from the group consisting of halogen, —OH, —OR m , —OC(O)NHR m , —OC(O)NR m R n , —SH, —SR m , —S(O)R m , —S(O) 2 R m , —S(O) 2 NH 2 , —S(O) 2 NHR m , —S(O) 2 NR m R n , —NHS(O) 2 R m , —NR m S(O) 2 R n , —C(O)NH 2 , —C(O)NHR m , —C(O)N(R m ) 2 , —C(O)R m , —NHC(O)R m , —NR m C(O)R n , —NHC(O)NH 2 , —NR m C(O)NH 2 , —NR m C(O)NHR n , —NHC(O)NHR m , —NR o C(O)NR m R n , —NHC(O)N(R m ) 2 , —CO 2 H, —CO 2 R m , —NHCO 2 R m , —NR m CO 2 R n , —CN, —NO 2 , —NH 2 , —NHR n , —NR m R n , —NR m S(O)NH 2 and —NR m S(O) 2 NHR n , where R m , R n , and R o are each independently unsubstituted C 1-6 alkyl.

2. A composition comprising a pharmaceutically acceptable carrier and a compound of claim 1 .

3. The compound of claim 1 , wherein Ar 1 is substituted or unsubstituted phenyl.

4. The compound of claim 1 , wherein Ar 2 has 0 to 4 substituents independently selected from the group consisting of halogen, unsubstituted or substituted C 1-6 alkyl, unsubstituted or substituted C 2-6 alkenyl, unsubstituted or substituted C 2-6 alkynyl, ═O, —CN, —NO 2 —OR 7 , —C(O)R 7 , —C(O)NR 8 R 9 , —NR 7 C(O)R 8 , —NR 8 R 9 , —S(O)R 7 , —S(O) 2 R 7 , —S(O) 2 NR 8 R 9 , —NR 7 S(O) 2 R 8 , —OC(O)R 7 , —CO 2 R 7 , —OC(O)NR 8 R 9 , —NR 7 C(O)NR 8 R 9 , —NR 7 CO 2 R 8 , unsubstituted or substituted 5- or 6-membered heteroaryl and a unsubstituted or substituted 3- to 7-membered heterocyclyl.

Assignments (2)
ASSIGNEE CHANGE OF ADDRESS Recorded Jun 27, 2023
From: CHEMOCENTRYX, INC.
To: CHEMOCENTRYX, INC.
Reel/Frame 064144/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2007
From: UNGASHE, SOLOMON; WRIGHT, JOHN JESSEN; PENNELL, ANDREW
To: CHEMOCENTRYX, INC.
Reel/Frame 020086/0873 →
Continuity (5)
Provisional Application 60570569 · May 12, 2004
Provisional Application 60570568 · May 12, 2004
Provisional Application 60570710 · May 12, 2004
Provisional Application 60571868 · May 17, 2004
Related Publication 20080161345A1 · Jul 3, 2008